Trial Information
A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
